<DOC>
	<DOCNO>NCT02264912</DOCNO>
	<brief_summary>The ongoing LAPCOR ( Laboratory AntiPlatelet efficacy Clinical Outcome Registry ) registry initiated 2008 tertiary care cardiac center , consecutive patient , underwent intracoronary stent implantation , include regardless whether percutaneous coronary intervention ( PCI ) perform urgent elective basis.Patients include registry sign informed consent participation . No exclusion criterion apply registry participation . Efficacy P2Y12 receptor antagonist measure quantitative flow cytometric analysis vasodilator-stimulated phosphoprotein ( VASP ) phosphorylation accord manufacturer protocol ( Platelet VASP ; Diagnostica Stago , Biocytex , Asni√®res , France ) FACScan flow cytometer ( Becton Dickinson ) . Occurrence major adverse cardiac event 30 day , 6-months one year follow investigate .</brief_summary>
	<brief_title>The Laboratory AntiPlatelet Efficacy Clinical Outcome Registry</brief_title>
	<detailed_description />
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>Patients stent PCI treat P2Y12 antagonist Written inform consent None</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>antiplatelet drug , percutanous coronary intervention , acute coronary syndrome , laboratory efficacy</keyword>
</DOC>